Vertex Falls as Cystic Fibrosis Drug Disappoints in Trial
This article is for subscribers only.
Vertex Pharmaceuticals Inc. fell after the company said its cystic fibrosis drug Kalydeco combined with an experimental drug helped patients’ breathing less than analysts had forecast.
After four weeks of treatment, patients who took Vertex’s VX-661 with Kalydeco saw a 4.4 percentage point increase in the amount of air they could exhale in 1 second, a measure of pulmonary function. At 12 weeks the improvement fell to 3 percentage points, Vertex said in a statement Monday.